Transcatheter aortic valve implantation with self-expandable prosthesis in the Republic of Moldova. The one year follow-up of the first ten patients.


  • ABRAS Marcel Universitatea de Stat de Medicină și Farmacie “Nicolae Testemițanu”, IMSP Institutul de Cardiologie
  • SUREV Artiom IMSP Institutul de Cardiologie
  • MOSCALU Vitalie IMSP Institutul de Cardiologie
  • CIOBANU Nicolae IMSP Institutul de Cardiologie
  • PASAT Ecaterina Universitatea de Stat de Medicină și Farmacie “Nicolae Testemițanu”,IMSP Institutul de Cardiologie
  • BEIU Catalina Universitatea de Stat de Medicină și Farmacie “Nicolae Testemițanu”



aortic stenosis, transcatheter aortic valve implantation, elderly patients


Aortic stenosis (AS) is a valvular heart disease commonly found in the elderly patients. Treatment should be initiated prompt after the diagnosis of symptomatic AS, due to its poor prognosis and a high death rate. Transcatheter aortic valve implantation (TAVI) is the elective treatment for elderly patients with AS and high surgical risk. This study aims to evaluate the preand post-TAVI echocardiographic parameters and the major adverse cardiovascular events (MACE) within the first 30 days and at 1 year, in the first 10 patients subjected to TAVI in the Republic of Moldova.


Rick A. Nishimura, Catherine M. Otto, Robert O.Bonow; 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63 (22) e57–e185

Baumgartner H. et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J.2017;38:2739-2791

Gry Wisthus Eveborn et al. The evolving epidemiology of valvular aortic stenosis. The Tromsø study, Heart. 2013;99(6):396-400. doi: 10.1136/heartjnl-2012-302265.

Strange G., Stewart S. et al. Poor Long-Term Survival in Patients With Moderate Aortic Stenosis. J Am Coll Cardiol. 2019; 74 (15):1851-63.

Alain Cribier et al. Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis. First Human Case Description. 2002;106:3006–3008.

Abras M. et. al. Transcatheter aortic valve implantation. First experience of minimally invasive treatment in the Republic of Moldova. Mold Med J. 2020;63(3):58-65. doi:10.5281/zenodo.3958567.

Roisin Mc Morrow et al. Assessing the safety and efficacy of TAVR compared to SAVR in low-to-intermediate surgical risk patients with aortic valve stenosis: An overview of reviews. Int. J. Cardiol. 2020 Sep 1; 314: 43–53. doi: 10.1016/j.ijcard.2020.04.022

Axel Linke et. al. Treatment of Aortic Stenosis With a Self-Expanding, Resheathable Transcatheter Valve OneYear Results of the International Multicenter Portico Transcatheter Aortic Valve Implantation System Study Circulation. Cardiovascular Interventions. 2018:11:2

Schulz E., Jabs A. et al. Transcatheter aortic valve implantation with the new-generation Evolut R™: Comparison with CoreValve® in a single center cohort. Int J Cardiol Heart & Vasculature. 2016;12,52-56.

Gil Marcus et al. Temporal Trends and Drivers of Heart Team Utilization in Transcatheter Aortic Valve Replacement: A Population‐Based Study in Ontario, Canada. Journal of the American Heart Association. 2021;10:e020741.

Karyofillis P, Kostopoulou A, Thomopoulou S, Habibi M, Livanis E, Karavolias G, Voudris V. Conduction abnormalities after transcatheter aortic valve implantation. J Geriatr Cardiol. 2018;15:105–112.

Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N. Engl J Med. 2017;376:1321–1331.

Joao Braghiroli et al., Transcatheter aortic valve replacement in low risk patients: a review of PARTNER 3 and Evolut low risk trials. Cardiovasc Diagn Ther. 2020; 10(1): 59–71. doi: 10.21037/cdt.2019.09.12

Godoy M, Mugharbil A, Anastasius M, Leipsic J. Cardiac computed tomography (CT) evaluation of valvular heart disease in transcatheter interventions. Curr Cardiol Rep. 2019;21:154. doi:10.1007/s11886-019-1241-6

Siontis GC, J–ni P, Pilgrim T et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64:129–40. doi: 10.1016/j.jacc.2014.04.033.

Martin B. Leon, M.D., Craig R. Smith, M.D., et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374:1609-20.

Philippe Généreux, Nicolo Piazza, Maria C. Alu, Tamim Nazif., et al. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J Am Coll Cardiol. 2021;77 (21) 2717–2746.

Toshinari Onishi, Kaoruko Sengoku, Yᵃˢᵘʰⁱʳᵒ Iᶜʰⁱᵇᵒʳⁱ, et al. The role of echocardiography in transcatheter aortic valve implantation. Cardiovasc Diagn Ther. 2018; 8(1): 3–17.

Christos Eftychiou, Nicolaos Eteocleous , Ioannis Zittis, Krikor Simamonian, et al. Outcomes of transfemoral transcatheter aortic valve implantation (TAVI) and predictors of thirty-day major adverse cardiovascular events (MACE) and one-year mortality. Hellenic J Cardiol. 2021;62(1):57-64.

Federico Marin 1 , Roberto Scarsini 2, et al. Aortic Valve Disease and Associated Complex CAD: The Interventional Approach. J. Clin. Med. 2021; 10, 946.

Tilman Stephan, Eva Thoma, et al. Impact of extent of coronary artery disease and percutaneous revascularization assessed by the SYNTAX score on outcomes following transcatheter aortic valve replacement. BMC Cardiovasc Disord. 2021;21:568. doi: 10.1186/s12872-021-02374-y.

Adrien Carmona, Benjamin Marchandot, et al. Impact of Incomplete Coronary Revascularization on Late Ischemic and Bleeding Events after Transcatheter Aortic Valve Replacement. J. Clin. Med. 2020;9,2267; doi:10.3390/jcm9072267.